title: Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients.
authors.forename: Teerha
authors.initials: T
authors.lastname: Piratvisuth
authors.forename: Patrick
authors.initials: P
authors.lastname: Marcellin
mesh_terms: D006801:Humans; D044466:Asian People / Q000235:genetics; D005838:Genotype; D006513:Hepatitis B e Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011994:Recombinant Proteins; D044465:White People / Q000235:genetics; D017326:Clinical Trials, Phase III as Topic
chemical_list: D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; C100416:peginterferon alfa-2a; D011092:Polyethylene Glycols; D011994:Recombinant Proteins